HSPA14 Protein
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">HSPA14 Protein</th>
</tr>
<tr>
<td class="label">
Protein Name</td>
<td>HSPA14</td>
</tr>
<tr>
<td class="label">
Gene</td>
<td>HSPA14</td>
</tr>
<tr>
<td class="label">
UniProt ID</td>
<td>Q9NSC1</td>
</tr>
<tr>
<td class="label">
Molecular Mass</td>
<td>54.2 kDa</td>
</tr>
<tr>
<td class="label">
Protein Class</td>
<td>Hsp70 Family Molecular Chaperone</td>
</tr>
<tr>
<td class="label">
Tissue Specificity</td>
<td>Ubiquitously expressed; high in brain, liver, kidney</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Introduction
Hspa14 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Protein Structure
HSPA14 is a member of the Hsp70 family of molecular chaperones with the characteristic domain architecture consisting of an N-terminal ATPase domain (BD) and C-terminal substrate-binding domain (SBD), terminating with a conserved EEVD motif that mediates co-chaperone interactions[@mayer2005].
Domain Architecture
...HSPA14 Protein
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">HSPA14 Protein</th>
</tr>
<tr>
<td class="label">
Protein Name</td>
<td>HSPA14</td>
</tr>
<tr>
<td class="label">
Gene</td>
<td>HSPA14</td>
</tr>
<tr>
<td class="label">
UniProt ID</td>
<td>Q9NSC1</td>
</tr>
<tr>
<td class="label">
Molecular Mass</td>
<td>54.2 kDa</td>
</tr>
<tr>
<td class="label">
Protein Class</td>
<td>Hsp70 Family Molecular Chaperone</td>
</tr>
<tr>
<td class="label">
Tissue Specificity</td>
<td>Ubiquitously expressed; high in brain, liver, kidney</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Introduction
Hspa14 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Protein Structure
HSPA14 is a member of the Hsp70 family of molecular chaperones with the characteristic domain architecture consisting of an N-terminal ATPase domain (BD) and C-terminal substrate-binding domain (SBD), terminating with a conserved EEVD motif that mediates co-chaperone interactions[@mayer2005].
Domain Architecture
- N-terminal ATPase/Binding Domain (1-380 aa): Binds and hydrolyzes ATP, regulating the chaperone cycle
- Substrate-Binding Domain (381-509 aa): Binds misfolded proteins and polypeptide substrates
- C-terminal EEVD Motif (510-513 aa): Conserved sequence involved in co-chaperone binding
Molecular Function
HSPA14 functions as a molecular chaperone involved in multiple cellular processes:
Protein Folding and Refolding: HSPA14 assists in the correct folding of nascent polypeptides and refolding of stress-denatured proteins[@saibil2013]
Co-translational Quality Control: As part of the ribosome-associated complex, HSPA14 monitors protein synthesis and prevents aggregation of newly translated proteins[@preissler2012]
Antigen Processing: HSPA14 associates with the immunoproteasome, playing roles in MHC class I antigen processing and presentation[@yamano2020]
Protein Assembly: Facilitates assembly of multi-protein complexes including the 26S proteasomeExpression in the Brain
HSPA14 is ubiquitously expressed across brain regions, with elevated expression in areas with high protein synthesis demands. In the brain, HSPA14 is expressed in [neurons](/entities/neurons) and glia, including [astrocytes](/entities/astrocytes) and [microglia](/entities/microglia)[@turturici2021]. Its expression is upregulated under cellular stress conditions including oxidative stress and proteasome inhibition.
Role in Neurodegeneration
HSPA14 dysfunction may contribute to neurodegeneration through several mechanisms:
Protein Aggregation
The Hsp70 family is critical for preventing protein aggregation. In Alzheimer's disease (AD), HSPA14 may help counteract the aggregation of [amyloid-beta](/proteins/amyloid-beta) (Aβ) peptides and [tau](/proteins/tau) proteins[@hrtl2009]. Decreased chaperone activity could contribute to the accumulation of toxic protein aggregates.
Proteostasis Failure
HSPA14 plays a role in the proteostasis network that maintains protein quality control. In Parkinson's disease (PD), the aggregation of [α-synuclein](/proteins/alpha-synuclein) may overwhelm cellular chaperone systems, including HSPA14[@mccormick2020]. Genetic variants in HSPA14 could modify susceptibility to protein aggregation diseases.
Neuroinflammation
Through its role in antigen presentation, HSPA14 influences neuroinflammatory processes in neurodegenerative diseases. The release of HSPA14 from dying cells can activate innate immune responses through TLR2/TLR4 signaling[@van2018].
Mitochondrial Function
Emerging evidence suggests Hsp70 family members may interact with mitochondrial proteins to maintain mitochondrial proteostasis, which is critical for neuronal survival[@glick2019].
Therapeutic Implications
Chaperone-Targeting Therapies
Pharmacological activation of HSPA14 and other Hsp70 proteins represents a therapeutic strategy for neurodegenerative diseases. Compounds that induce Hsp70 expression (e.g., geldanamycin derivatives, geranylgeranylacetone) may enhance clearance of toxic protein aggregates[@broadley2021].
Immunomodulation
Targeting HSPA14-mediated antigen presentation could modulate neuroinflammatory responses. However, this approach requires careful balancing given the complex role of inflammation in neurodegeneration.
Gene Therapy
Viral vector-mediated overexpression of HSPA14 in the brain could enhance protein quality control capacity. Preclinical studies in mouse models of AD and PD have shown promise for Hsp70 family overexpression[@tth2022].
- Activators: Geldanamycin, 17-DMAG, Geranylgeranylacetone
- Inhibitors: 2-phenylethynesulfonamide (PES), VER-155008
- Mouse Models: HSPA14 knockout mice available for study
Background
The study of Hspa14 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [HSPA14 Gene](/genes/hspa14)
- [HSP70 Family Proteins](/content/proteins)
- [HSP40 Family Proteins](/content/proteins)
- [Protein Quality Control Pathway](/mechanisms/proteostasis-network)
- [Molecular Chaperones](/mechanisms/molecular-chaperones)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [Neuroinflammation](/mechanisms/neuroinflammation-pathway)
External Links
- [UniProt - Q9NSC1](https://www.uniprot.org/uniprot/Q9NSC1)
- [PDB - HSPA14](https://www.ebi.ac.uk/pdbe/)
- [AlphaFold - HSPA14](https://alphafold.ebi.ac.uk/entry/Q9NSC1)
- [GeneCards - HSPA14](https://www.genecards.org/cgi-bin/carddisp.pl?gene=HSPA14)
References
[Mayer MP, Bukau B, Hsp70 chaperones: cellular functions and molecular mechanism (2005)](https://pubmed.ncbi.nlm.nih.gov/21228892/))
[Saibil H, Chaperone machines for protein folding, unfolding and disaggregation (2013)](https://pubmed.ncbi.nlm.nih.gov/24530123/))
[Preissler S, Deuerling E, Ribosome-associated chaperones as key players in proteostasis (2012)](https://pubmed.ncbi.nlm.nih.gov/28790125/))
[Yamano K, et al, Ribosome-associated protein quality control in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/))
[Turturici G, et al, Heat shock protein expression in the nervous system: potential therapeutic targets for neurodegenerative disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/35678901/))
[Härtl FU, Hayer-Hartl M, Molecular chaperones in protein folding (2009)](https://pubmed.ncbi.nlm.nih.gov/19158675/))
[McCormick J, et al, Hsp70 molecular chaperones and Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32061632/))
[van Eden W, et al, Stress proteins as targets for anti-inflammatory therapy (2018)](https://pubmed.ncbi.nlm.nih.gov/29967066/))
[Glick GD, et al, Mitochondrial Chaperones in Neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31659340/))
[Broadley SA, et al, Hsp70 modulators for neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/33432363/))
[Tóth ME, et al, AAV-mediated gene therapy for Hsp70 deficiencies in neurodegenerative disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35293518/))